|Items||Size （2mg）||Size（5mg X 2）|
|Particle size||2 μm||2 μm|
|Physical appearance||Powder mixture||Powder mixture|
|Amount of Coupled Protein||>1000 pmol (49 μg) Nucleocapsid protein/mg beads||>1000 pmol (49 μg) Nucleocapsid protein/mg beads|
|Binding Capacity||>130 pmol (20 μg) Anti-Nucleocapsid antibody/mg beads||>130 pmol (20 μg) Anti-Nucleocapsid antibody/mg beads|
|Formulation||PBS, pH7.4, with 10% Trehalose||PBS, pH7.4, with 10% Trehalose|
|Reconstitution||2 mL sterile deionized water (1 mg beads/mL)||5 mL sterile deionized water (1 mg beads/mL)|
The pre-coupled magnetic beads coupled with biotinylated SARS-CoV-2 Nucleocapsid protein to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody from cell or serum sample. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This very first SARS-CoV-2 Nucleocapsid protein-coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready to use products could greatly save your time and hassle.
This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
See Certificate of Analysis (CoA) for detailed instruction.
Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.
Please avoid more than 3 freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
Antibody Purification: 1. Resuspend the lyophilized beads by adding the buffer of choice. 2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein. 3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads. 4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.
The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
Immobilized 49 μg SARS-CoV-2 Nucleocapsid protein to 1 mg Beads can bind the Anti-SARS-CoV-2 Nucleocapsid Antibody with an EC50 of 0.6712 μg/mL (QC tested).
Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the SARS-CoV-2 Nucleocapsid Protein-coupled Magnetic Beads (Cat.No. MBS-K017) and the Anti-SARS-CoV-2 Nucleocapsid Antibody showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.
Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the SARS-CoV-2 Nucleocapsid Protein-coupled Magnetic Beads (Cat.No. MBS-K017) and the Anti-SARS-CoV-2 Nucleocapsid Antibody showed little deviation from the unfreeze-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.